Lupin receives FDA Approval for Generic SOLODYN® Tablets

Mumbai / Baltimore, December 2nd, 2011: Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Minocycline hydrochloride extended-release tablets 45 mg, 55 mg, 90 mg and 135 mg strengths as well as tentative approval for its Minocycline HCl extended release tablets 65 mg, 80 mg, 105 mg and 115 mg strengths from the U.S. Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Medicis Pharmaceutical Corporation’s (Medicis) SOLODYN® (Minocycline HCI, USP) extended-release tablets.

SOLODYN® is an oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older. Medicis’s SOLODYN® (Minocycline HCI, USP) Extended-release tablets had sales of USD 750 million as per IMS Sept 2011 data.

About Lupin Limited

Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million (USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.

About Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is committed to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

For more information, please contact:

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshegorawara@lupinpharma.com or

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management’s expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

*SOLODYN®* is a registered trademark of Medecis Pharmaceutical Corporation.